Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > ARCHIVE
ARCHIVE
- Bill for Healthcare Reform to Be Presented to Diet Next Year -2-
October 8, 2001
- Chugai to Withdraw from Medical Device Business
October 8, 2001
- Mochida, JCR Submit NDA for Thrombomodulin
October 8, 2001
- Major Objective Is Reinforcement of Ethical Drug Business: Taisho President
October 8, 2001
- Shionogi to Need 2 Years Before Obtaining Results of Restructuring
October 8, 2001
- Number of Diabetes Patients to Increase to 4.3 Mil. in 2010: Mr Nagae of Aventis
October 8, 2001
- BUSINESS NEWS IN BRIEF -1-
October 8, 2001
- BUSINESS NEWS IN BRIEF -2-
October 8, 2001
- Council Listens to 3 Bodies on Its Deregulation Proposals
October 1, 2001
- To Accelerate Growth Via Synergism: Taisho, Tanabe
October 1, 2001
- Jovi, Wing to Merge on October 1
October 1, 2001
- Sumisho Retail Stores to Merge with Asahi Medix Next Spring
October 1, 2001
- JSMEBE Meeting: New Hemodynamic Monitoring Methods Presented
October 1, 2001
- Taisho to Introduce New Open POS System "Support VAN21"
October 1, 2001
- Enhanced Safety Measures Provide Business Opportunity for IMI: President Tsumuga
October 1, 2001
- NEDO to Give Grants to 4 Healthcare-related Projects
October 1, 2001
- MEDICAL DEVICE NEWS IN BRIEF
October 1, 2001
- European Office to Be Set Up Soon, Following US One: Mr Takusagawa of Kyorin
October 1, 2001
- DIAGNOSTIC NEWS IN BRIEF
October 1, 2001
- BULLETIN
October 1, 2001
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…